Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

March 27, 2015 8:41 PM ET


Company Overview of Advaxis, Inc.

Company Overview

Advaxis, Inc., a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of Lm-LLO cancer immunotherapies in the United States. The Lm-LLO immunotherapy platform technology stimulates the immune system to induce antigen-specific anti-tumor immune responses involving innate and adaptive arms of the immune system by inhibiting the T-cells, tregs, and myeloid-derived suppressor cells, and MDSC to promote immunologic tolerance of cancer cells in the tumor. Its lead product ADXS-HPV, an Lm-LLO immunotherapy product candidate used for the treatment of human papilloma virus (HPV) associated cancers, completed its Phase II study. The company is also develop...

305 College Road East

Princeton, NJ 08540

United States

Founded in 2002

20 Employees





Key Executives for Advaxis, Inc.

Chief Executive Officer, President and Director
Age: 49
Total Annual Compensation: $398.8K
Chief Operating Officer and Executive Vice President
Age: 45
Total Annual Compensation: $285.0K
Chief Scientific Officer and Executive Vice President
Age: 54
Total Annual Compensation: $331.2K
Compensation as of Fiscal Year 2014.

Advaxis, Inc. Key Developments

Advaxis, Inc. Presents Preliminary Data from a Phase 1/2 Trial of ADXS-HPV

Advaxis, Inc. presented preliminary data from the Phase 1/2 clinical study of its lead immunotherapy product candidate, ADXS-HPV (ADXS11-001), in 10 patients with HPV-associated locally advanced anal cancer indicating that all patients who have completed treatment in the study have had a complete response with no evidence of recurrence to date (follow-up ranging from 0.5 â “ 24 months). The preliminary data also show that the investigational immunotherapy was well tolerated by the treated patients, and all treatment-related toxicities were within 24 hours of dosing, the most frequent of which include chills/rigors, fever and nausea. The data were highlighted in an oral presentation by Kimberly Perez, M.D., Assistant Professor of Medicine at the Alpert Medical School, Brown University, during the recent International Anal Neoplasia Society (IANS) Scientific Meeting 2015, in Atlanta, Georgia.

Advaxis, Inc. Presents at 25th Annual Institutional Investor Conference, Mar-19-2015 09:05 AM

Advaxis, Inc. Presents at 25th Annual Institutional Investor Conference, Mar-19-2015 09:05 AM. Venue: The University Club, 1 W 54th St, New York, NY 10019, United States.

Advaxis, Inc. Presents at Cowen and Company 35th Annual Healthcare Conference, Mar-04-2015 10:00 AM

Advaxis, Inc. Presents at Cowen and Company 35th Annual Healthcare Conference, Mar-04-2015 10:00 AM. Venue: The Boston Marriott Copley Place, Boston, Massachusetts, United States. Speakers: Daniel J. O'Connor, Chief Executive Officer, President and Director.

Similar Private Companies By Industry

Company Name Region
Martek Biosciences Boulder Corporation United States
Bioarray Therapeutics, Inc. United States
Envisia Therapeutics Inc. United States
NellOne Therapeutics, Inc. United States
Innovative Cardiovascular Solutions, LLC United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Advaxis, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at